Skip to Main content Skip to Navigation
Master Thesis

Étude rétrospective de l'impact de la conciliation médicamenteuse dans les essais cliniques en oncologie

Abstract : Information on drug-drug interactions (DDIs) from clinical trials is non-exhaustive and the risk to include patients with prohibited medications does exist. It was decided to conduct medication reconciliation (MR) by pharmacist prior to the enrollment of patients, before starting investigational treatment. The objective of this study is to evaluate the impact of medication reconciliation. All patients enrolled in clinical trials receiving MR by pharmacist between September 2015 and February 2020 were included. To conduct MR, a minimum of 3 sources were used to perform an exhaustive list of medications: patient’s medical record, patient interview and community pharmacy dispensing history. Protocols and investigator’s brochures provided by the sponsor were consulted to define prohibited or monitored drugs. In this study, 501 MR were conducted, 35% of drugs were discovered by pharmacist in 369 patients (74%). Pharmaceutical analysis identified 346 DDIs: 188 monitored drugs and 158 prohibited. More than half of the prohibited medications were herbal drugs. Most prohibited drugs were stopped and 6% substituted. Among prohibited or monitored drugs, 51% were revealed by MR and unknown by oncologists. In conclusion, MR reduces the risk of DDIs with the investigational drugs, limits protocol deviations and helps secure patient care. Sponsors recognized benefits of MR and finance this activity in extra costs. MR takes place in multidisciplinary patient care through the collaboration between oncologists and pharmacists.
Document type :
Master Thesis
Complete list of metadatas

Cited literature [110 references]  Display  Hide  Download

https://dumas.ccsd.cnrs.fr/dumas-02988316
Contributor : Frédérique Gambade <>
Submitted on : Wednesday, November 4, 2020 - 4:37:39 PM
Last modification on : Saturday, November 14, 2020 - 3:10:59 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : 2021-10-12

Please log in to resquest access to the document

Identifiers

  • HAL Id : dumas-02988316, version 1

Collections

Citation

Barbara Lortal. Étude rétrospective de l'impact de la conciliation médicamenteuse dans les essais cliniques en oncologie. Sciences du Vivant [q-bio]. 2020. ⟨dumas-02988316⟩

Share

Metrics

Record views

8